Baxter to divest biopharma solutions business to Advent International and Warburg Pincus for $4.25 bn
Express Pharma
MAY 8, 2023
Under the terms of the definitive agreement, Baxter will receive $4.25 Under the terms of the definitive agreement, Baxter will receive $4.25 The transaction is expected to close in the second half of 2023, subject to receipt of customary regulatory approvals and satisfaction of other customary closing conditions.
Let's personalize your content